Cost Evaluation of Inhaler Therapies Used in Respiratory Diseases: 1998--2015 Period in Turkey  Banu Bayar, MD, Nurcan Uman Kutkan, MPharm, Esra Şafak Yılmaz, MSc, Çiğdem Tolun, MPharm, Engin Doğan, MPharm, MSc, Enver Kağan Atikeler, MPharm, MSc, Elif Hilal Vural, MD, Salih Babacan, MD, Nurgül Karabekmez, MD, Aslıhan Beyan, MPharm, MSc, İsmail Mert Vural, MD, İpek Kıvılcım Oğuzülgen, MD, Güven Bektemür, MD, Simten Malhan, PhD, Rabia Kahveci, MD, Sedat Altın, MD, Ali Alkan, MD, Hakan Eroğlu, MPharm, PhD, Hakkı Gürsöz, MD  Value in Health Regional Issues  Volume 13, Pages 31-38 (September 2017) DOI: 10.1016/j.vhri.2017.07.004 Copyright © 2017 Terms and Conditions

Fig. 1 The cumulative number of molecules, products, and brands of inhaler medicines in the R03 group that were licensed at any time before the end of 2015, annually. Value in Health Regional Issues 2017 13, 31-38DOI: (10.1016/j.vhri.2017.07.004) Copyright © 2017 Terms and Conditions

Fig. 2 (A) Annual box sales. (B) Sales amounts (in TL) of the subgroups of inhaler pharmaceuticals used in the treatment of obstructive respiratory diseases according to their pharmacological activity in the Turkish market between the years 1998 and 2015. ICS, inhaled corticosteroid; ICS + LABA, combination of inhaled corticosteroid and long-acting β2 agonist; LABA, long-acting β2 agonist; LAMA, long-acting antimuscarinic agonist; SABA, short-acting β2 agonist; SABA + SAMA, combination of short-acting β2 agonist and short-acting antimuscarinic agonist; SAMA, short-acting antimuscarinic agonist; TL, Turkish lira. Value in Health Regional Issues 2017 13, 31-38DOI: (10.1016/j.vhri.2017.07.004) Copyright © 2017 Terms and Conditions

Fig. 3 (A) Annual box sales. (B) Sales amounts (in TL) of the subgroups of inhaler pharmaceuticals used in the treatment of obstructive respiratory diseases according to their forms in the Turkish market between the years 1998 and 2015. DPI, dry-powder inhalers; MDI, metered-dose inhalers; TL, Turkish lira. Value in Health Regional Issues 2017 13, 31-38DOI: (10.1016/j.vhri.2017.07.004) Copyright © 2017 Terms and Conditions

Fig. 4 (A) Projected box sales. (B) Sales amounts (in TL) between the years 1998 and 2018 using the data for 2010–2015 of inhaler pharmaceuticals used in the treatment of obstructive respiratory diseases in the Turkish market. Value in Health Regional Issues 2017 13, 31-38DOI: (10.1016/j.vhri.2017.07.004) Copyright © 2017 Terms and Conditions